Endocrine Abstracts

Pasireotide is a second-generation, multireceptor-targeted somatostatin receptor ligand and is approved for the treatment of patients with Cushing’s Didease (CD) for whom surgery has failed or is not an option. This retrospective single center study aims to report the efficacy, side effects and follow-up of the treatment with pasireotide alone or in combination with cabergoline in patients without remission after transsphenoidal surgery. Among 187 patients with CD, 15 pat...